VRAX:NASDAQVirax Biolabs Group Limited Analysis
Data as of 2026-08-13 - not real-time
$2.85
Latest Price
9/10Risk
Risk Level: High
Executive Summary
The moving-average structure behind Virax Biolabs Group Limited is bearish at $2.85, with short-term averages lagging the long-term ones. It has gained 4.0% over the past 30 days. Momentum indicators put RSI at 43.6 (neutral) with MACD reading bullish. Watch $2.55 as support and $4.11 as the nearer resistance level.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 777.2% above the current quote. Revenue is growing at 684.9%.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 261.4%, a beta of 2.32 and a maximum drawdown of 86.7%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 777.2% above the current quote. Revenue is growing at 684.9%.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 261.4%, a beta of 2.32 and a maximum drawdown of 86.7%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.
Top Market Events
Virax Biolabs Group Limited NASDAQ:VRAX stock is up during Thursday’s premarket session, as the company has signed a...Virax Biolabs Group Limited "Virax" or the "Company" Nasdaq: VRAX today closed its previously announced exercise of...Virax Biolabs Group Limited NASDAQ: VRAX "Virax" or the "Company" today announced that its wholly owned subsidiary,...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 6.35
- MACD momentum is positive
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 6.35
- Analyst targets imply +777.2% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- Analyst targets imply +777.2% versus the current price
- Negative return on equity of -78.6%
- Revenue growth of +684.9%
Key Metrics & Analysis
Financial Health
Revenue Growth684.90%
P/E Ratio-0.5
ROE-78.65%
ROA-54.23%
Debt/Equity5.65
P/B Ratio0.2
Op. Cash Flow$-4621892
Free Cash Flow$-3477016
Industry P/E30.1
Technical Analysis
TrendBearish
RSI43.6
Support$2.55
Resistance$4.11
MA 20$3.09
MA 50$3.66
MA 200$6.35
MACDBullish
VolumeDecreasing
Fear & Greed Index95.18
Valuation
Target Price$25.00
Upside/Downside777.19%
GradeUndervalued
TypeBlend
Risk Assessment
Beta2.32
Volatility261.42%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.